Literature DB >> 33664897

Current status and role of programmed ventricular stimulation in patients without sustained ventricular arrhythmias and reduced ejection fraction: Analysis of the Japan cardiac device treatment registry database.

Hisashi Yokoshiki1, Akihiko Shimizu2, Takeshi Mitsuhashi3, Kohei Ishibashi4, Tomoyuki Kabutoya5, Yasuhiro Yoshiga6, Ritsuko Kohno7, Haruhiko Abe7, Akihiko Nogami8.   

Abstract

BACKGROUND: The aim of this study was to clarify the current status and role of programmed ventricular stimulation in patients without sustained ventricular arrhythmias and reduced left ventricular ejection fraction (LVEF).
METHODS: The follow-up data of the Japan cardiac device treatment registry (JCDTR) was analyzed in 746 patients with LVEF ≦35% and no prior history of sustained ventricular arrhythmias who underwent de novo implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D) implantation between January 2011 and August 2015.
RESULTS: Electrophysiological study (EPS) with programmed ventricular stimulation had been performed before the device implant in 118 patients (15.8%, EPS group). During the mean follow-up of 21 ± 12 months, the rate of freedom from any death and appropriate defibrillator therapy was not significantly different between EPS group (n = 118) and No EPS group (n = 628). NYHA class II-IV, and QRS duration were negatively associated with performing EPS. Among patients in the EPS group, the rate of ventricular tachycardia (VT)/ventricular fibrillation (VF) induction was 48%. The inducibility was not a predictor of appropriate defibrillator therapy, whereas BNP ≧535 pg/mL and no use of amiodarone were significantly associated with a risk of the appropriate therapy.
CONCLUSION: EPS for induction of VT/VF had been performed in about 16% of patients with reduced LVEF before primary prevention ICD/CRT-D implantation. Elevated BNP levels and no use of amiodarone, but not inducibility of VT/VF, appeared to be associated with appropriate defibrillator therapy in these populations.
© 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society.

Entities:  

Keywords:  cardiac resynchronization therapy with a defibrillator (CRT‐D); electrophysiological study (EPS); implantable cardioverter‐defibrillator (ICD); primary prevention; ventricular fibrillation (VF); ventricular tachycardia (VT)

Year:  2020        PMID: 33664897      PMCID: PMC7896472          DOI: 10.1002/joa3.12468

Source DB:  PubMed          Journal:  J Arrhythm        ISSN: 1880-4276


  19 in total

1.  Reduced risk of life-threatening ventricular tachyarrhythmias with cardiac resynchronization therapy: relationship to left ventricular ejection fraction.

Authors:  Valentina Kutyifa; Arthur J Moss; Scott D Solomon; Scott McNitt; Mehmet K Aktas; Alon Barsheshet; Bela Merkely; Wojciech Zareba; Ilan Goldenberg
Journal:  Eur J Heart Fail       Date:  2015-07-14       Impact factor: 15.534

2.  Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators.

Authors:  A E Buxton; K L Lee; L DiCarlo; M R Gold; G S Greer; E N Prystowsky; M F O'Toole; A Tang; J D Fisher; J Coromilas; M Talajic; G Hafley
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. AVID Investigators. Antiarrhythmics Versus Implantable Defibrillators.

Authors:  M J Domanski; S Sakseena; A E Epstein; A P Hallstrom; M A Brodsky; S Kim; S Lancaster; E Schron
Journal:  J Am Coll Cardiol       Date:  1999-10       Impact factor: 24.094

5.  Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.

Authors:  James P Daubert; Wojciech Zareba; W Jackson Hall; Claudio Schuger; Andrew Corsello; Angel R Leon; Mark L Andrews; Scott McNitt; David T Huang; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

6.  Trends in the use of implantable cardioverter-defibrillator and cardiac resynchronization therapy device in advancing age: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Kohei Ishibashi; Tomoyuki Kabutoya; Yasuhiro Yoshiga; Ritsuko Kohno; Haruhiko Abe; Akihiko Nogami
Journal:  J Arrhythm       Date:  2020-06-08

7.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

8.  Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial.

Authors:  Douglas L Packer; Jordan M Prutkin; Anne S Hellkamp; L Brent Mitchell; Robert C Bernstein; Freda Wood; John P Boehmer; Mark D Carlson; Robert P Frantz; Steve E McNulty; Joseph G Rogers; Jill Anderson; George W Johnson; Mary Norine Walsh; Jeanne E Poole; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  Circulation       Date:  2009-11-16       Impact factor: 29.690

9.  Reduction in inappropriate therapy and mortality through ICD programming.

Authors:  Arthur J Moss; Claudio Schuger; Christopher A Beck; Mary W Brown; David S Cannom; James P Daubert; N A Mark Estes; Henry Greenberg; W Jackson Hall; David T Huang; Josef Kautzner; Helmut Klein; Scott McNitt; Brian Olshansky; Morio Shoda; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2012-11-06       Impact factor: 91.245

10.  Trends and determinant factors in the use of cardiac resynchronization therapy devices in Japan: Analysis of the Japan cardiac device treatment registry database.

Authors:  Hisashi Yokoshiki; Akihiko Shimizu; Takeshi Mitsuhashi; Hiroshi Furushima; Yukio Sekiguchi; Tetsuyuki Manaka; Nobuhiro Nishii; Takeshi Ueyama; Norishige Morita; Takashi Nitta; Ken Okumura
Journal:  J Arrhythm       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.